Published: June 2022 | Report Code: 11347 | Available Format: PDF
The global needle-free injection systems market was valued at $151.0 million in 2021, and it is projected to expand with a CAGR of 13.3% during 2021–2030, to generate $466.2 million by 2030. This can be ascribed to the worldwide growing diabetic population, which generates high demand for self-injection devices; increasing prevalence of needlestick injuries; and fear of needles among people.
Prefilled needle-free injection devices are expected to grow with the faster CAGR, more than 14%, during 2021–2030. This is primarily because the majority of these prefilled syringes are automated, reducing the risk of physical handling and ensuring a safer use. Moreover, the U.S. is the largest revenue contributor to the prefilled needle-free injectors market, due to the large diabetic and chronic disease patient base in the country. Furthermore, these advanced systems help patients to reduce the risk of contamination or human-caused dosing errors. Due to the aforementioned factors, the demand for prefilled needle-free injectors is increasing across the world.
In 2021, the liquid-based needle-free injection systems held around 70% share in the market. This can be ascribed to the technological advancements, and the easy usage of needle-free injection technology, which makes it more popular in the market.
The upsurge in needlestick injuries is projected to boost the demand for needle-free injectors. These injectors reduce the risk of needlestick injuries and help patients overcome needle fear. They also restrict the transmission of infectious diseases by avoiding cross-contamination. Needlestick injuries can cause contagious diseases such as HIV-AIDS, Hepatitis-B, and Hepatitis-C. To reduce the cases of contagious diseases, needle-free injection systems have gained popularity.
Market Size in 2021
Revenue Forecast in 2030
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
By Product; By Type; By Technology; By Usability; By Site of Delivery; By Application; By End User; By Region
Explore more about this report - Request free sample
The jet-based technology contributes the largest revenue to the needle-free injection systems market, and the category is projected to expand with a CAGR of around 14% during 2021–2030. This can be attributed to its benefits, including less time being spent on preparing and administering the medication, fewer needlestick injuries, convenience in usage and aesthetics, and a lower chance of disease spreading.
The laser-powered category is projected to exhibit healthy growth during the forecast period. This growth can be attributed to its ability to precisely manage drug delivery quantity and depth, and its high adoption rates in aesthetic skin treatment techniques.
Reusable needle-free injection devices are accounted for higher revenue in the market. This is primarily ascribed to the feature of refilling injectors for multiple uses. On the other hand, disposable needle-free injectors are expected to grow faster in the coming years. This is due to the disposable feature of these needles that avoid needlestick injuries and cross-contamination.
Patients with chronic conditions who use self-injection devices have more control over their treatment schedules, allowing them to become more independent and freer in their social, personal, and working activities. Self-injection may provide psychological advantages over professional administration, such as increased self-esteem. Eliminating the need for frequent injections at a clinic or hospital, ultimately keeps costs down for both the patients and medical systems. Thus, the cost-effectiveness of self-injection devices has been a primary driver of the needle-free injection systems market growth.
Needle-free injection systems are highly used for insulin delivery. This is ascribed to the huge diabetic population base that uses a large number of insulin delivery devices and the fear of needles or syringes among people. Furthermore, since there is no risk of needlestick injury, it is a viable option to be used at home and in healthcare settings. As a result, the demand for needle-free injectors for insulin delivery is increasing.
The subcutaneous injectors category accounted for the largest revenue share in the market in 2021, and it is expected to maintain its position during the forecast period as well. This is because when a medicine is administered, it moves into the capillaries and is delivered to the bloodstream from there.
Hospitals and clinics are the largest end user of needle-free injection devices and the category accounts for the highest market share. This is attributed to the technical advancements, rise in demand for vaccinations, and increase in usage of medication delivery systems due to the high-patient traffic in hospitals and clinics. Whereas, the fastest growth is observed in the home care settings category during the forecast period, due to the rapid upsurge in the number of diabetic patients.
The North American needle-free injection systems market held the largest revenue share, of over 40%, in 2021, and it is expected to lead the market in the future as well. This is due to the presence of well-developed healthcare infrastructure, high level of patient awareness, increase in cases of chronic diseases, and high R&D spending on needle-free injection technologies.
On the other hand, the APAC market will register the fastest growth during the forecast period. This can be ascribed to the rise in disposable income and increase in public healthcare expenditure in developing economies of the region. Moreover, the surging adoption rate of needle-free injectors for vaccination of several medical conditions is another factor responsible for the regional market growth.
Key players in the market have been engaged in partnerships and clinical trials to gain a competitive edge. For instance:
The report offers comprehensive market segmentation analysis along with the revenue estimation for the period 2017–2030.
Based on Product
Based on Type
Based on Technology
Based on Usability
Based on Delivery Site
Based on Application
Based on End User
The needle-free injection systems market size stood at $151.0 million in 2021.
During 2021–2030, the growth rate of the needle-free injection systems market will be 13.3%.
Hospitals and clinics are the largest end users of needle-free injection systems.
The major drivers of the needle-free injection systems market include the worldwide growing diabetic population, which generates high demand for self-injection devices; increasing prevalence of needlestick injuries; and fear of needles among people.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws